Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has lifted the ...

Vanda ( ($VNDA) ) has shared an update. On December 4, 2025, Vanda Pharmaceuticals announced that the FDA has lifted the partial clinical hold on ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced the following updates regarding tradipitant for motion ...

Vanda advances with strong Fanapt growth, late-stage catalysts, GLP-1 potential, higher investment and solid balance sheet support. Read why VNDA stock is a buy.

Investing.com -- Vanda Pharmaceuticals (NASDAQ:VNDA) stock rose 11% in after-hours trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) has lifted a partial ...

Vanda ( ($VNDA) ) just unveiled an announcement. On November 28, 2025, Vanda Pharmaceuticals announced updates regarding its drug tradipitant for ...

Vanda Pharmaceuticals said the Food and Drug Administration has lifted the partial clinical hold on its motion sickness drug tradipitant . The decision allows the Washington, D.C., company to extend ...

Tradipitant could become the first new pharmacologic treatment for motion sickness in over 40 years.

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 ...

US biotech Vanda Pharmaceuticals (Nasdaq: VNDA) says the American medicines regulator has extended its expedited re-review of ...

English National Opera has appointed three new Greater Manchester-based trustees, further strengthening the organisation's ...

FDA accelerates re-review of Vanda's tradipitant and begins label talks, keeping its motion sickness drug on track for key 2025 decisions.